On May 6, 2025, leading financial services company Goldman Sachs made adjustments to its assessment of Twist Bioscience (TWST, Financial), reaffirming the "Buy" rating but lowering the price target. Analyst Matthew Sykes maintained the "Buy" rating previously issued, indicating continued confidence in the stock's potential.
Despite maintaining the rating, Goldman Sachs reduced the price target for Twist Bioscience (TWST, Financial) from $55.00 to $48.00. This adjustment reflects a 12.73% decrease in the target price, representing a recalibrated outlook based on current market conditions.
Twist Bioscience (TWST, Financial), listed on NASDAQ, continues to be closely watched by investors and analysts alike as it endeavors to innovate within the bioscience sector. The price target adjustment by Goldman Sachs provides strategic insights into the company's future valuations.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for Twist Bioscience Corp (TWST, Financial) is $51.47 with a high estimate of $62.00 and a low estimate of $44.00. The average target implies an upside of 52.59% from the current price of $33.73. More detailed estimate data can be found on the Twist Bioscience Corp (TWST) Forecast page.
Based on the consensus recommendation from 13 brokerage firms, Twist Bioscience Corp's (TWST, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Twist Bioscience Corp (TWST, Financial) in one year is $59.61, suggesting a upside of 76.73% from the current price of $33.73. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Twist Bioscience Corp (TWST) Summary page.
